Immunological Response During HAART and Determinants of Current CD4⁺ T-Cell Count Among HIV/AIDS Patients Attending University of Gondar Referral Hospital, Northwest Ethiopia

References

• Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277(5322):112–116. doi:10.1126/science.277.5322.1129204894
   PubMed Web of Science ®Google Scholar
• Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376(9734):49–62. doi:10.1016/S0140-6736(10)60676-920609987
   PubMed Web of Science ®Google Scholar
• Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the centers for disease control and prevention, National Institutes of Health, and HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2014;58(9):1308–1311. doi:10.1093/cid/ciu09424585567
   PubMed Web of Science ®Google Scholar
• Fokam J, Billong SC, Jogue F, et al. Immuno-virological response and associated factors amongst HIV-1 vertically infected adolescents in Yaounde-Cameroon. PLoS One. 2017;12(11):e0187566. doi:10.1371/journal.pone.018756629112991
   PubMed Web of Science ®Google Scholar
• He L, Pan X, Dou Z, et al. The factors related to CD4+ T-cell recovery and viral suppression in patients who have low CD4+ T cell counts at the initiation of HAART: a retrospective study of the national HIV treatment sub-database of Zhejiang Province, China, 2014. PLoS One. 2016;11(2):e0148915. doi:10.1371/journal.pone.014891526900702
   PubMedGoogle Scholar
• Casotti JA, Passos LN, Oliveira FJ, Cerutti C. Factors associated with paradoxical immune response to antiretroviral therapy in HIV infected patients: a case-control study. BMC Infect Dis. 2011;11(1):306. doi:10.1186/1471-2334-11-30622047047
   PubMedGoogle Scholar
• French experts group’s recommendations for medical management of hiv infection: highlights and recommendations; 2008 Available from: https://solidarites-sante.gouv.fr/IMG/pdf/synthese_rapport_yeni_version_anglaise.pdf. Accessed July 14, 2020.
   Google Scholar
• Bartlett J. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department Health Human Services Panel on Antiretroviral Guidelines Adult Adolescents. 2008;42–43.
   Google Scholar
• Mendoza Y, Mewa JC, Martínez AA, et al. HIV-1 antiretroviral drug resistance mutations in treatment-naive and experienced Panamanian subjects: impact on the national use of EFV-based schemes. PLoS One. 2016;11(4):e0154317. doi:10.1371/journal.pone.015431727119150
   PubMedGoogle Scholar
• Meintjes G, Maartens G. Guidelines for antiretroviral therapy in adults. South Afr J HIV Med. 2012;13(3):114–133. doi:10.4102/sajhivmed.v13i3.125
   Web of Science ®Google Scholar
• Gezie LD. Predictors of CD4 count over time among HIV patients initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia: multilevel analysis. BMC Res Notes. 2016;9(1):377. doi:10.1186/s13104-016-2182-427475982
   PubMedGoogle Scholar
• Kokeb M, Degu G. Immunological response of HIV-infected children to highly active antiretroviral therapy at Gondar university hospital, north-western Ethiopia. Ethiop J Health Sci. 2016;26(1):25–30. doi:10.4314/ejhs.v26i1.626949313
   PubMedGoogle Scholar
• Asfaw A, Ali D, Eticha T, Alemayehu A, Alemayehu M, Kindeya F. CD4 cell count trends after commencement of antiretroviral therapy among HIV-infected patients in Tigray, Northern Ethiopia: a retrospective cross-sectional study. PLoS One. 2015;10(3):e0122583. doi:10.1371/journal.pone.012258325816222
   PubMed Web of Science ®Google Scholar
• Lawn SD, Myer L, Bekker L-G, Wood R. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis. 2006;6(1):59. doi:10.1186/1471-2334-6-5916551345
   PubMedGoogle Scholar
• Smith CJ, Sabin CA, Youle MS, et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis. 2004;190(10):1860–1868. doi:10.1086/42507515499544
   PubMed Web of Science ®Google Scholar
• Dou Z, Xu J, Jiao JH, et al. Gender difference in 2-year mortality and immunological response to ART in an HIV-infected Chinese population, 2006–2008. PLoS One. 2011;6(8):e22707. doi:10.1371/journal.pone.002270721857947
   PubMedGoogle Scholar
• Anude CJ, Eze E, Onyegbutulem HC, et al. Abimiku Al: immuno-virologic outcomes and immuno-virologic discordance among adults alive and on antiretroviral therapy at 12 months in Nigeria. BMC Infect Dis. 2013;13(1):113. doi:10.1186/1471-2334-13-11323452915
   PubMedGoogle Scholar
• Abrogoua DP, Kablan BJ, Kamenan BAT, Aulagner G, N’Guessan K, Zohoré C. Assessment of the impact of adherence and other predictors during HAART on various CD4 cell responses in resource-limited settings. Patient Prefer Adherence. 2012;6:227. doi:10.2147/PPA.S2650722536059
   PubMed Web of Science ®Google Scholar
• Kiwuwa MS, Walker AS, Oja H, et al., DART Trial Team. The impact of first-year adherence to antiretroviral therapy on long‐term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe. Tropical Med Int Health. 2012;17(5):584–594. doi:10.1111/j.1365-3156.2012.02974.x
   PubMed Web of Science ®Google Scholar
• Teshome W, Assefa A. Predictors of immunological failure of antiretroviral therapy among HIV infected patients in Ethiopia: a matched case-control study. PLoS One. 2014;9(12):e115125. doi:10.1371/journal.pone.011512525536416
   PubMedGoogle Scholar
• Ayalew MB, Kumilachew D, Belay A, et al. First-line antiretroviral treatment failure and associated factors in HIV patients at the University of Gondar Teaching Hospital, Gondar, Northwest Ethiopia. HIV/AIDS. 2016;8:141.27621669
   PubMedGoogle Scholar
• Yirdaw KD, Hattingh S. Prevalence and predictors of immunological failure among HIV patients on HAART in southern Ethiopia. PLoS One. 2015;10(5):e0125826. doi:10.1371/journal.pone.012582625961732
   PubMed Web of Science ®Google Scholar
• 90-90-90 An ambitious treatment target to help end the AIDS epidemic. Geneva Switzerland Available from: https://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf. Accessed 714, 2020.
   Google Scholar
• Population and housing census 2007 report, Amhara, Part I: population size and characteristics. Available from: http://microdata.worldbank.org/index.php/catalog/2747/download/39220. Accessed 714, 2020.
   Google Scholar
• Ayele G, Tessema B, Amsalu A, Ferede G, Yismaw G. Prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia. BMC Immunol. 2018;19(1):37. doi:10.1186/s12865-018-0278-430558580
   PubMedGoogle Scholar
• National guidelines on second-line ART for adults and adolescents India: department of AIDS control national AIDS control organization ministry of health & family welfare Government of India. Available from: http://naco.gov.in/sites/default/files/National%20Guidelines%20on%20Second-line%20and%20Alternative%20First-line%20ART%20For%20Adults%20and%20Adolescents%20May%202013_0.pdf. Accessed 714, 2020.
   Google Scholar
• World Health Organization. March 2014 Supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach; 2014 Available from: https://apps.who.int/iris/bitstream/handle/10665/104264/9789241506830_eng.pdf. Accessed July 15,2020.
   Google Scholar
• Bokretsion GB, Endalkachew N, Getachew KA. HIV/AIDS treatment failure and its determinant factors among first-line HAART patients at Felege-Hiwot Referral Hospital, Bahir Dar, Northwest Ethiopia. J AIDS Clin Res. 2017;8:11.
   Google Scholar
• Mulu A, Liebert UG, Maier M. Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children. BMC Infect Dis. 2014;14(1):28. doi:10.1186/1471-2334-14-2824422906
   PubMedGoogle Scholar
• Annison L, Dompreh A, Adu-Sarkodie Y. The immunological response of HIV-positive patients initiating HAART at the Komfo Anokye Teaching Hospital, Kumasi, Ghana. Ghana Med J. 2013;47(4):164.24669021
   PubMedGoogle Scholar
• Appay V, Sauce D. Immune activation and inflammation in HIV‐1 infection: causes and consequences. J Pathol. 2008;214(2):231–241. doi:10.1002/path.227618161758
   PubMed Web of Science ®Google Scholar
• Kannan VP, Babu Anand C, Nehru D. A study of antiretroviral therapy outcomes in a tertiary care center in thanjavur medical college hospital, Southern India. J. Evid. Based Med. Healthc. 2017; 4(38), 2273-2279. doi: 10.18410/jebmh/2017/446 Available from: https://jebmh.com/latest_articles/96125. Accessed Juy 15, 2020.
   Google Scholar
• Florence E, Lundgren J, Dreezen C, et al. EuroSIDA Study Group. Factors associated with a reduced CD4 lymphocyte count response to haart despite full viral suppression in the eurosida study. HIV Med. 2003;4(3):255–262.12859325
   PubMedGoogle Scholar
• García F, de Lazzari E, Plana M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. JAIDS. 2004;36(2):702–713. doi:10.1097/00126334-200406010-0000715167289
   PubMedGoogle Scholar
• Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to< 500 cells/µL in HIV Type 1 infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005;41(3):361–372. doi:10.1086/43148416007534
   PubMed Web of Science ®Google Scholar
• Robbins GK, Spritzler JG, Chan ES, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS clinical trials group protocol 384. Clin Infect Dis. 2009;48(3):350–361. doi:10.1086/59588819123865
   PubMedGoogle Scholar
• Kanters S, Nachega J, Funk A, et al. CD4 (+) T-cell recovery after initiation of antiretroviral therapy in a resource-limited setting: a prospective cohort analysis. Antivir Ther. 2014;19(1):31–39. doi:10.3851/IMP2670
   PubMed Web of Science ®Google Scholar
• Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44(3):441–446. doi:10.1086/51074617205456
   PubMed Web of Science ®Google Scholar
• Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355. doi:10.1371/journal.pone.008135524367482
   PubMed Web of Science ®Google Scholar
• Palella F Jr, Armon C, Chmiel J, et al. CD4 cell count at initiation of ART, long-term likelihood of achieving CD4> 750 cells/mm3 and mortality risk. J Antimicrobial Chemother. 2016;71(9):2654–2662. doi:10.1093/jac/dkw196
   PubMed Web of Science ®Google Scholar
• Liang H, Wu H, Carroll RJ. The relationship between virologic and immunologic responses in AIDS clinical research using mixed‐effects varying‐coefficient models with measurement error. Biostatistics. 2003;4(2):297–312. doi:10.1093/biostatistics/4.2.29712925523
   PubMed Web of Science ®Google Scholar
• Pakker NG, Notermans DW, De Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med. 1998;4(2):208–214. doi:10.1038/nm0298-2089461195
   PubMed Web of Science ®Google Scholar
• Twizerimana AP, Mwatha J, Musabyimana JP, Kayigi E, Harelimana JD, Karanja SM, Mutesa L. Immunological profiles in HIV positive patients following highly active antiretroviral treatment initiation in Kigali,Rwanda. East African Medical Journal 2014 Dec 3;91 (8):261-6.
   Google Scholar
• Nash D, Katyal M, Brinkhof MW, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: collaborative analysis of prospective studies: the antiretroviral therapy in lower-income countries (ART-LINC) collaboration of the international epidemiological databases to evaluate AIDS. AIDS. 2008;22(17):2291.18981768
   PubMed Web of Science ®Google Scholar
• Kwobah CM, Braitstein P, Koech JK, et al. Factors associated with late engagement to HIV care in Western Kenya: a cross-sectional study. J Int Association Providers AIDS Care. 2016;15(6):505–511. doi:10.1177/2325957414567682
   PubMedGoogle Scholar
• Mojumdar K, Vajpayee M, Chauhan NK, Mendiratta S. Late presenters to HIV care and treatment, identification of associated risk factors in HIV-1 infected Indian population. BMC Public Health. 2010;10(1):416. doi:10.1186/1471-2458-10-41620626905
   PubMedGoogle Scholar
• World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy; 2017 Available from: https://apps.who.int/iris/bitstream/handle/10665/255884/9789241550062-eng.pdf. Accessed July 15,2020.
   Google Scholar
• Galdas PM, Cheater F, Marshall P. Men and health help‐seeking behavior: a literature review. J Adv Nurs. 2005;49(6):616–623. doi:10.1111/j.1365-2648.2004.03331.x15737222
   PubMed Web of Science ®Google Scholar
• Braitstein P, Boulle A, Nash D, et al. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Women’s Health. 2008;17(1):47–55. doi:10.1089/jwh.2007.0353
   PubMed Web of Science ®Google Scholar
• Gea-Banacloche JC, Clifford HL. Immune reconstitution in HIV infection. AIDS. 1999;13:S2538.
   Web of Science ®Google Scholar